Gedeon Richter will pay up to SFr445m ($462.8m) for PregLem, a biopharmaceutical company focused on the treatment of gynaecological conditions and infertility.
Gedeon Richter, a Hungary-based drugs company, has agreed to acquire Switzerland-based peer PregLem from its investors that included Sutrepa, an affiliate of medical company Ipsen.
Gedeon Richter will pay up to SFr445m ($462.8m), with SFr150m in cash initially and the rest dependent on performance of the biopharmaceutical company focused on the treatment of gynaecological conditions and infertility.
Sutrepa took a minority investment in PregLem in June 2007 as part of a partnership agreement and as the Swiss company raised…
